Literature DB >> 21042887

Chemoradiotherapy for cervical cancer in 2010.

Ann H Klopp1, Patricia J Eifel.   

Abstract

The introduction of concurrent chemotherapy and radiotherapy for the definitive treatment of cervical cancer constituted a major advance in the management of cervical cancer, resulting in a significant improvement in local control, progression-free survival, and overall survival. Since the publication of the results of seminal trials demonstrating the benefits of platinum-based chemotherapy, investigations of new cytotoxic and targeting agents have continued. The success of these studies has been limited in part because the side effects of standard platinum-based chemoradiation regimens already approach the limits of tolerability. Future progress will depend on identifying new agents without overlapping toxic effects, improving supportive care, and minimizing the toxic effects of radiation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21042887     DOI: 10.1007/s11912-010-0134-z

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  69 in total

1.  The role of FDG-PET/CT imaging after radiation therapy.

Authors:  Perry W Grigsby
Journal:  Gynecol Oncol       Date:  2007-08-28       Impact factor: 5.482

2.  C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability.

Authors:  S Nasu; K K Ang; Z Fan; L Milas
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-10-01       Impact factor: 7.038

3.  Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis.

Authors:  Elizabeth A Kidd; Barry A Siegel; Farrokh Dehdashti; Janet S Rader; David G Mutch; Matthew A Powell; Perry W Grigsby
Journal:  J Clin Oncol       Date:  2010-03-22       Impact factor: 44.544

4.  Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix.

Authors:  W A Peters; P Y Liu; R J Barrett; R J Stock; B J Monk; J S Berek; L Souhami; P Grigsby; W Gordon; D S Alberts
Journal:  J Clin Oncol       Date:  2000-04       Impact factor: 44.544

5.  Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial.

Authors:  J E Kurtz; A-C Hardy-Bessard; M Deslandres; S Lavau-Denes; R Largillier; C Roemer-Becuwe; B Weber; C Guillemet; D Paraiso; E Pujade-Lauraine
Journal:  Gynecol Oncol       Date:  2009-02-15       Impact factor: 5.482

6.  Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial.

Authors:  Frederick B Stehman; Shamshad Ali; Henry M Keys; Laila I Muderspach; Weldon E Chafe; Donald G Gallup; Joan L Walker; Deborah Gersell
Journal:  Am J Obstet Gynecol       Date:  2007-11       Impact factor: 8.661

7.  Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.

Authors:  Robert A Burger; Michael W Sill; Bradley J Monk; Benjamin E Greer; Joel I Sorosky
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

8.  Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.

Authors:  Patricia J Eifel; Kathryn Winter; Mitchell Morris; Charles Levenback; Perry W Grigsby; Jay Cooper; Marvin Rotman; David Gershenson; David G Mutch
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544

9.  Retrospective analysis of concomitant Cisplatin during radiation in patients aged 55 years or older for treatment of advanced cervical cancer: a gynecologic oncology group study.

Authors:  Charles Kunos; Chunqiao Tian; Steven Waggoner; Peter G Rose; Rachelle Lanciano
Journal:  Int J Gynecol Cancer       Date:  2009-10       Impact factor: 3.437

10.  Randomized trial of epirubicin and cisplatin chemotherapy followed by pelvic radiation in locally advanced cervical cancer. Cervical Cancer Study Group of the Asian Oceanian Clinical Oncology Association.

Authors:  M H Tattersall; V Lorvidhaya; V Vootiprux; A Cheirsilpa; F Wong; T Azhar; H P Lee; S B Kang; A Manalo; M S Yen
Journal:  J Clin Oncol       Date:  1995-02       Impact factor: 44.544

View more
  7 in total

Review 1.  'BRCAness' and its implications for platinum action in gynecologic cancer.

Authors:  Franco Muggia; Tamar Safra
Journal:  Anticancer Res       Date:  2014-02       Impact factor: 2.480

2.  CXCL10 enhances radiotherapy effects in HeLa cells through cell cycle redistribution.

Authors:  Ling-Lin Yang; Bi-Qiong Wang; Lan-Lan Chen; Hui-Qun Luo; Jing-Bo Wu
Journal:  Oncol Lett       Date:  2011-11-04       Impact factor: 2.967

3.  Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer.

Authors:  Ann H Klopp; Jennifer Moughan; Lorraine Portelance; Brigitte E Miller; Mohammad R Salehpour; Evangeline Hildebrandt; Jenny Nuanjing; David D'Souza; Luis Souhami; William Small; Rakesh Gaur; Anuja Jhingran
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-05-01       Impact factor: 7.038

4.  Combining CXCL10 gene therapy and radiotherapy improved therapeutic efficacy in cervical cancer HeLa cell xenograft tumor models.

Authors:  Ming Zhao; Qian Ma; Jinhui Xu; Shaozhi Fu; Lanlan Chen; Biqiong Wang; Jingbo Wu; Linglin Yang
Journal:  Oncol Lett       Date:  2015-05-27       Impact factor: 2.967

5.  Concurrent Chemoradiotherapy without Brachytherapy in Locally Advanced Cervical Cancer.

Authors:  Sima Kadkhodayan; Fatemeh Homaei Shandiz; Mehdi Seilanian Toussi; Monavar Afzal Aghaee; Farnoosh Farshidi; Parvane Dehghan
Journal:  Iran J Cancer Prev       Date:  2013

6.  Bioinformatics Screening of Potential Biomarkers from mRNA Expression Profiles to Discover Drug Targets and Agents for Cervical Cancer.

Authors:  Md Selim Reza; Md Harun-Or-Roshid; Md Ariful Islam; Md Alim Hossen; Md Tofazzal Hossain; Shengzhong Feng; Wenhui Xi; Md Nurul Haque Mollah; Yanjie Wei
Journal:  Int J Mol Sci       Date:  2022-04-02       Impact factor: 5.923

7.  Metadata analysis to explore hub of the hub-genes highlighting their functions, pathways and regulators for cervical cancer diagnosis and therapies.

Authors:  Md Selim Reza; Md Alim Hossen; Md Harun-Or-Roshid; Mst Ayesha Siddika; Md Hadiul Kabir; Md Nurul Haque Mollah
Journal:  Discov Oncol       Date:  2022-08-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.